Pharsight

Novo patents expiration

1. Macrilen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6861409 NOVO Growth hormone secretagogues
Aug, 2022

(1 year, 2 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Oct, 2027

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 20, 2024

Drugs and Companies using MACIMORELIN ACETATE ingredient

Market Authorisation Date: 20 December, 2017

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

MACRILEN family patents

Family Patents

2. Ozempic patents expiration

OZEMPIC's oppositions filed in EPO
OZEMPIC Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(2 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 8 months ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 8 months ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 8 months ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(3 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(7 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(1 year, 10 months from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(3 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(8 years from now)

US10335462 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jan 16, 2023
New Dosing Schedule (D) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to imp...

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

3. Rybelsus patents expiration

RYBELSUS's oppositions filed in EPO
RYBELSUS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(2 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10960052 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
Dec, 2031

(8 years from now)

US9278123 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US10086047 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US11382957 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US10933120 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(9 years from now)

US10278923 NOVO Oral dosing of GLP-1 compounds
May, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 20 September, 2019

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage

RYBELSUS family patents

Family Patents

4. Saxenda patents expiration

SAXENDA's oppositions filed in EPO
SAXENDA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(1 year, 1 month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 8 months ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 8 months ago)

US8846618 NOVO Stable formulation of modified GLP-1
Jun, 2022

(1 year, 3 months ago)

US6899699

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 3 months ago)

US8672898

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 3 months ago)

US9486588

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 3 months ago)

US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1
Dec, 2022

(9 months ago)

US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs
Feb, 2023

(7 months ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(3 months ago)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(2 months from now)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(7 months from now)

US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(1 year, 1 month from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(1 year, 10 months from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US8114833

(Pediatric)

NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(2 years from now)

US8684969

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Apr, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US9616180

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

US9861757

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Jul, 2026

(2 years from now)

US9108002

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9775953

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(3 years from now)

US10220155

(Pediatric)

NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jan, 2027

(3 years from now)

US8920383

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(3 years from now)

USRE46363

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Feb, 2027

(3 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(3 years from now)

US9687611

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Aug, 2027

(3 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Mar, 2028

(4 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(8 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(8 years from now)

US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(13 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Dec 4, 2023

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

5. Wegovy patents expiration

WEGOVY's oppositions filed in EPO
WEGOVY Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(2 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(9 years from now)

US10888605 NOVO GLP-1 compositions and uses thereof
Aug, 2038

(14 years from now)

US11318191 NOVO GLP-1 compositions and uses thereof
Feb, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 4, 2024
New Patient Population (NPP) Dec 23, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage

WEGOVY family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic